{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:56:29Z","timestamp":1760648189301,"version":"3.44.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,25]]},"DOI":"10.7759\/cureus.90992","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T03:43:42Z","timestamp":1756179822000},"source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the Unexpected: A Case of Synergistic Drug Reaction to Cannabidiol"],"prefix":"10.7759","author":[{"given":"Aiman","family":"Balouch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Osama","family":"Muslim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Saad","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Naqash","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.18231\/j.jpbs.2024.020","article-title":"Cannabinoid pharmacology: research on medicinal cannabins and its therapeutic application","volume":"12","author":"Kulkarni VA","year":"2024","unstructured":"Kulkarni VA, Nimje HP, Varhade PP, et al.. Cannabinoid pharmacology: research on medicinal cannabins and its therapeutic application. J Pharma Biol Sci. 2024, 12:135-43. 10.18231\/j.jpbs.2024.020","journal-title":"J Pharma Biol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13627","article-title":"Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis","volume":"293","author":"Lo LA","year":"2023","unstructured":"Lo LA, Christiansen A, Eadie L, et al.. Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis. J Intern Med. 2023, 293:724-52. 10.1111\/joim.13627","journal-title":"J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/jat.4646","article-title":"Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes","volume":"44","author":"Striz A","year":"2024","unstructured":"Striz A, Zhao Y, Sepehr E, et al.. Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. J Appl Toxicol. 2024, 44:1595-605. 10.1002\/jat.4646","journal-title":"J Appl Toxicol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management","volume":"97","author":"Bj\u00f6rnsson HK","year":"2022","unstructured":"Bj\u00f6rnsson HK, Bj\u00f6rnsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022, 97:26-31. 10.1016\/j.ejim.2021.10.035","journal-title":"Eur J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","volume":"36","author":"Balachandran P","year":"2021","unstructured":"Balachandran P, Elsohly M, Hill KP. Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review. J Gen Intern Med. 2021, 36:2074-84. 10.1007\/s11606-020-06504-8","journal-title":"J Gen Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2397847320922944","article-title":"Is cannabidiol hepatotoxic or hepatoprotective: a review","volume":"4","author":"Stohs SJ","year":"2024","unstructured":"Stohs SJ, Ray SD. Is cannabidiol hepatotoxic or hepatoprotective: a review. Toxicol Res App. 2024, 4:10.1177\/2397847320922944","journal-title":"Toxicol Res App"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00726-4","article-title":"A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy","volume":"34","author":"Ben-Menachem E","year":"2020","unstructured":"Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al.. A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy. CNS Drugs. 2020, 34:661-72. 10.1007\/s40263-020-00726-4","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.950","article-title":"A phase 1 open-label, fixed-sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects","volume":"10","author":"Thai C","year":"2021","unstructured":"Thai C, Tayo B, Critchley D. A phase 1 open-label, fixed-sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021, 10:1279-89. 10.1002\/cpdd.950","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin S","year":"2021","unstructured":"Nasrin S, Watson CJ, Perez-Paramo YX, Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab Dispos. 2021, 49:1070-80. 10.1124\/dmd.121.000442","journal-title":"Drug Metab Dispos"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2959","article-title":"Flucloxacillin is a weak inducer of CYP3A4 in healthy adults and 3D spheroid of primary human hepatocytes","volume":"114","author":"Iversen DB","year":"2023","unstructured":"Iversen DB, Dunvald AD, Jespersen DM, et al.. Flucloxacillin is a weak inducer of CYP3A4 in healthy adults and 3D spheroid of primary human hepatocytes. Clin Pharmacol Ther. 2023, 114:434-45. 10.1002\/cpt.2959","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/OAEM.S24962","article-title":"Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?","volume":"3","author":"Kalsi SS","year":"2011","unstructured":"Kalsi SS, Wood DM, Waring WS, Dargan PI. Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?. Open Access Emerg Med. 2011, 3:69-76. 10.2147\/OAEM.S24962","journal-title":"Open Access Emerg Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2008.01.018","article-title":"A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells","volume":"8","author":"Lee CY","year":"2008","unstructured":"Lee CY, Wey SP, Liao MH, Hsu WL, Wu HY, Jan TR. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol. 2008, 8:732-40. 10.1016\/j.intimp.2008.01.018","journal-title":"Int Immunopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24091694","article-title":"Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model","volume":"24","author":"Ewing LE","year":"2019","unstructured":"Ewing LE, Skinner CM, Quick CM, et al.. Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. Molecules. 2019, 24:1694. 10.3390\/molecules24091694","journal-title":"Molecules"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7688","article-title":"A case of toxicity from cannabidiol gummy ingestion","volume":"12","author":"Bass J","year":"2020","unstructured":"Bass J, Linz DR. A case of toxicity from cannabidiol gummy ingestion. Cureus. 2020, 12:e7688. 10.7759\/cureus.7688","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0114","article-title":"Observed impact of long-term consumption of oral cannabidiol on liver function in healthy adults","volume":"8","author":"Kaufmann R","year":"2023","unstructured":"Kaufmann R, Aqua K, Lombardo J, Lee M. Observed impact of long-term consumption of oral cannabidiol on liver function in healthy adults. Cannabis Cannabinoid Res. 2023, 8:148-54. 10.1089\/can.2021.0114","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042370","article-title":"The role of cannabidiol in liver disease: a systemic review","volume":"25","author":"Chen S","year":"2024","unstructured":"Chen S, Kim JK. The role of cannabidiol in liver disease: a systemic review. Int J Mol Sci. 2024, 25:2370. 10.3390\/ijms25042370","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2020.22.3\/jmarcu","article-title":"The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report","volume":"22","author":"Marcu J","year":"2020","unstructured":"Marcu J. The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report\u2029. Dialogues Clin Neurosci. 2020, 22:289-93. 10.31887\/DCNS.2020.22.3\/jmarcu","journal-title":"Dialogues Clin Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16730","article-title":"Clinical guidance for cannabidiol-associated hepatotoxicity: a narrative review","volume":"39","author":"Eadie L","year":"2024","unstructured":"Eadie L, Lo LA, Boivin M, Deol JK, MacCallum CA. Clinical guidance for cannabidiol-associated hepatotoxicity: a narrative review. J Gastroenterol Hepatol. 2024, 39:2522-32. 10.1111\/jgh.16730","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376593-unveiling-the-unexpected-a-case-of-synergistic-drug-reaction-to-cannabidiol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T03:43:45Z","timestamp":1756179825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376593-unveiling-the-unexpected-a-case-of-synergistic-drug-reaction-to-cannabidiol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.90992","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}